HC Wainwright Analysts Boost Earnings Estimates for OLMA

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright boosted their Q1 2025 earnings estimates for shares of Olema Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.59) for the quarter, up from their previous forecast of ($0.64). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12.

Separately, Oppenheimer reiterated an “outperform” rating and set a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $4.23 on Friday. The company has a market cap of $242.37 million, a price-to-earnings ratio of -1.93 and a beta of 2.11. The stock’s fifty day moving average price is $5.09 and its 200 day moving average price is $8.33. Olema Pharmaceuticals has a 1 year low of $3.94 and a 1 year high of $16.62.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. Victory Capital Management Inc. boosted its position in Olema Pharmaceuticals by 9.9% in the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after purchasing an additional 76,720 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Olema Pharmaceuticals by 80.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock worth $1,237,000 after purchasing an additional 94,651 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after purchasing an additional 207,565 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Olema Pharmaceuticals by 10.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after purchasing an additional 97,428 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were bought at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the transaction, the insider now owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.